Structure-optimized 4-trifluoromethylquinoline derivatives: Dual enhancement of SGK1 inhibition and anti-prostate cancer efficacy
Authors:
- 28 May 2026
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 180, 110032
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Guizhou Province (KXJZ[2025]014)
- Natural Science Foundation of Guizhou Province (QKHZDZX[2024]015)
This publication has 40 references indexed in Scilit:
- Design, synthesis, and in silico study of VEGFR-2 and HDAC dual acting quinazoline based molecules for anticancer evaluationBioorganic Chemistry, 2026
- Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?Bioorganic Chemistry, 2026
- Exploring Quinoline-linked Chalcones as broad-Spectrum antimicrobial agents: Synthesis, antibacterial, antifungal, molecular docking, pharmacokinetics, and DFT investigationBioorganic Chemistry, 2025
- Prostate CancerJAMA, 2025
- Discovery of novel 4-trifluoromethyl-2-anilinoquinoline derivatives as potential anti-cancer agents targeting SGK1Molecular Diversity, 2024
- Discovery of Novel Anti‐Resistance AR Antagonists Guided by Funnel Metadynamics SimulationAdvanced Science, 2024
- Bioanalytical method validation, biopharmaceutical and pharmacokinetic evaluation of GSK-650394, a serum- and glucocorticoid-regulated kinase 1 inhibitorArabian Journal of Chemistry, 2023
- Serum and glucocorticoid inducible protein kinases (SGKs): a potential target for cancer interventionActa Pharmaceutica Sinica B, 2018
- Design, synthesis and insecticidal activities of dihydropyridine-fused neonicotinoids compounds with trifluoromethyl groupResearch on Chemical Intermediates, 2015
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate CancerDiscover Oncology, 2014